Iterative Health

Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). We use advanced machine learning and computer vision to interpret endoscopic images along with other types of data, helping clinicians to better assess patients with potential GI problems. This gives practitioners enhanced capabilities in the detection, annotation, disease scoring and treatment of GI related diseases. 

 Iterative Health is initially applying these advances towards standardizing disease severity characterization for inflammatory bowel disease. Ultimately, the company aims to establish more meaningful endpoints to serve as better predictors of both therapeutic response and disease outcomes. The company is headquartered in Cambridge, Massachusetts. 

Our team is on a mission to develop technology that can benefit patients anywhere, regardless of socioeconomic or geographic barriers.

By using machine learning and artificial intelligence to augment human perception, we’re creating a higher worldwide standard for gastrointestinal care. Our strategy is scalable. It’s sustainable. Most importantly, it’s attainable.

We believe that timely access to quality healthcare should be embraced as nothing less than a basic human right. We believe our progress as a company will play an important role in making this vision a reality.